A multivariate vaccine could be available in the fall «kleinezeitung.at

A vaccine that works against all possible variants of the coronavirus: This is the goal of many vaccine manufacturers. Biontech/Pfizer is now trying to get this done as quickly as possible.

10:30 PM, April 13, 2022

Pfizer CEO Albert Burla may have this in mind until autumn A new vaccine that contains both Against the omicron variable as well as against other variables Protect. It’s easy to do something about Omicron,” Borla said at the IFPMA event. Developing an effective vaccine against all previously known variants requires more science and technology.

He hopes such a vaccine will be available by the fall. What the world really needs, says Burla Vaccine works for a year, where people who have had other booster vaccines will be vaccinated. “We are working on it.” Technically, however, developing a vaccine that is effective against all variants known to date is a major challenge, due to the nature of the virus.

Biontech/Pfizer and Moderna, the two companies that produce mRNA Covid-19 vaccines, already indicated with the advent of the omicron variant that they were working on an adapted vaccine. It was originally supposed to be available by March or the end of the first quarter. Regarding Biontech/Pfizer, the clinical study began in January.

There doesn’t seem to be any rush for the fourth stitch at the moment: Das National Vaccination Council (NIG) recommends IV vaccination in new assessment Only for groups at risk. This applies to people over 80 years old and people over 65 years old who have pre-existing diseases. They should be vaccinated again as soon as four months, ideally six months after the third bite, according to a committee paper available to the American Psychological Association. However, no one else should be denied the vaccination either.